Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfacon-2 Injection in low-replication chronic HBV infection
CTR20213197Phase 3Completed
- Sponsor
- Chongqing Fujin Biopharmaceutical
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfacon-2 in hepatitis B (HBV), sponsored by Chongqing Fujin Biopharmaceutical. Started Dec 2021; status: completed.
02
Drugs
peginterferon alfacon-2
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on CTR20213197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213197.